BioScrip (BIOS) Misses Q2 EPS by 14c, Revs Modestly Lower; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
BioScrip Reports Second Quarter 2017 Financial Results
August 8, 2017 8:01 AM EDTNet revenue of $218.1 million, including core product mix of 73.1% compared to 60.3% in the prior year Net loss from continuing operations of $28.7 million, compared to $8.3 million in the prior year, reflecting increased non-cash expenses and interest Adjusted EBITDA of $10.0 million, nearly doubling from the first quarter of 2017 Operating Cash Flow of $6.5 million, reflecting $23 million of operational and working capital improvements over the prior year Liquidity of $50.5 million, including $40.5 million of cash, compared to $16.0 million at March 31, 2017 Restructuring expenses of $3.9 million, primarily costs related to the ongoing optimization of the Companys workforce The Company reaffirms EBITDA guidance and updates revenue guidance
... More